nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoversetamide—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000761	0.000761	CcSEcCtD
Gadoversetamide—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000761	0.000761	CcSEcCtD
Gadoversetamide—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000759	0.000759	CcSEcCtD
Gadoversetamide—Feeling abnormal—Leflunomide—systemic scleroderma	0.000756	0.000756	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000756	0.000756	CcSEcCtD
Gadoversetamide—Fatigue—Mycophenolic acid—systemic scleroderma	0.000755	0.000755	CcSEcCtD
Gadoversetamide—Nausea—Mometasone—systemic scleroderma	0.000753	0.000753	CcSEcCtD
Gadoversetamide—Anorexia—Lisinopril—systemic scleroderma	0.000752	0.000752	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.00075	0.00075	CcSEcCtD
Gadoversetamide—Pain—Mycophenolic acid—systemic scleroderma	0.000749	0.000749	CcSEcCtD
Gadoversetamide—Constipation—Mycophenolic acid—systemic scleroderma	0.000749	0.000749	CcSEcCtD
Gadoversetamide—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000748	0.000748	CcSEcCtD
Gadoversetamide—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000744	0.000744	CcSEcCtD
Gadoversetamide—Hyperglycaemia—Prednisone—systemic scleroderma	0.000743	0.000743	CcSEcCtD
Gadoversetamide—Cough—Mycophenolate mofetil—systemic scleroderma	0.000739	0.000739	CcSEcCtD
Gadoversetamide—Hypotension—Lisinopril—systemic scleroderma	0.000737	0.000737	CcSEcCtD
Gadoversetamide—Dizziness—Captopril—systemic scleroderma	0.000736	0.000736	CcSEcCtD
Gadoversetamide—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000733	0.000733	CcSEcCtD
Gadoversetamide—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000731	0.000731	CcSEcCtD
Gadoversetamide—Urticaria—Leflunomide—systemic scleroderma	0.000729	0.000729	CcSEcCtD
Gadoversetamide—Abdominal pain—Leflunomide—systemic scleroderma	0.000725	0.000725	CcSEcCtD
Gadoversetamide—Body temperature increased—Leflunomide—systemic scleroderma	0.000725	0.000725	CcSEcCtD
Gadoversetamide—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000721	0.000721	CcSEcCtD
Gadoversetamide—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000721	0.000721	CcSEcCtD
Gadoversetamide—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000721	0.000721	CcSEcCtD
Gadoversetamide—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000721	0.000721	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000718	0.000718	CcSEcCtD
Gadoversetamide—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000718	0.000718	CcSEcCtD
Gadoversetamide—Hypersensitivity—Azathioprine—systemic scleroderma	0.000716	0.000716	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000716	0.000716	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000716	0.000716	CcSEcCtD
Gadoversetamide—Insomnia—Lisinopril—systemic scleroderma	0.000713	0.000713	CcSEcCtD
Gadoversetamide—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000712	0.000712	CcSEcCtD
Gadoversetamide—Paraesthesia—Lisinopril—systemic scleroderma	0.000708	0.000708	CcSEcCtD
Gadoversetamide—Vomiting—Captopril—systemic scleroderma	0.000708	0.000708	CcSEcCtD
Gadoversetamide—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000705	0.000705	CcSEcCtD
Gadoversetamide—Dyspnoea—Lisinopril—systemic scleroderma	0.000703	0.000703	CcSEcCtD
Gadoversetamide—Rash—Captopril—systemic scleroderma	0.000702	0.000702	CcSEcCtD
Gadoversetamide—Dermatitis—Captopril—systemic scleroderma	0.000701	0.000701	CcSEcCtD
Gadoversetamide—Somnolence—Lisinopril—systemic scleroderma	0.000701	0.000701	CcSEcCtD
Gadoversetamide—Headache—Captopril—systemic scleroderma	0.000697	0.000697	CcSEcCtD
Gadoversetamide—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000697	0.000697	CcSEcCtD
Gadoversetamide—Dyspepsia—Lisinopril—systemic scleroderma	0.000694	0.000694	CcSEcCtD
Gadoversetamide—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000692	0.000692	CcSEcCtD
Gadoversetamide—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000692	0.000692	CcSEcCtD
Gadoversetamide—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000691	0.000691	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000691	0.000691	CcSEcCtD
Gadoversetamide—Asthma—Methotrexate—systemic scleroderma	0.000688	0.000688	CcSEcCtD
Gadoversetamide—Decreased appetite—Lisinopril—systemic scleroderma	0.000685	0.000685	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000681	0.000681	CcSEcCtD
Gadoversetamide—Fatigue—Lisinopril—systemic scleroderma	0.00068	0.00068	CcSEcCtD
Gadoversetamide—Shock—Mycophenolate mofetil—systemic scleroderma	0.00068	0.00068	CcSEcCtD
Gadoversetamide—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000677	0.000677	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000676	0.000676	CcSEcCtD
Gadoversetamide—Hypersensitivity—Leflunomide—systemic scleroderma	0.000676	0.000676	CcSEcCtD
Gadoversetamide—Constipation—Lisinopril—systemic scleroderma	0.000674	0.000674	CcSEcCtD
Gadoversetamide—Pain—Lisinopril—systemic scleroderma	0.000674	0.000674	CcSEcCtD
Gadoversetamide—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000674	0.000674	CcSEcCtD
Gadoversetamide—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000671	0.000671	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000668	0.000668	CcSEcCtD
Gadoversetamide—Diarrhoea—Azathioprine—systemic scleroderma	0.000665	0.000665	CcSEcCtD
Gadoversetamide—Haemoglobin—Prednisone—systemic scleroderma	0.000662	0.000662	CcSEcCtD
Gadoversetamide—Nausea—Captopril—systemic scleroderma	0.000661	0.000661	CcSEcCtD
Gadoversetamide—Haemorrhage—Prednisone—systemic scleroderma	0.000659	0.000659	CcSEcCtD
Gadoversetamide—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000659	0.000659	CcSEcCtD
Gadoversetamide—Asthenia—Leflunomide—systemic scleroderma	0.000658	0.000658	CcSEcCtD
Gadoversetamide—Hallucination—Prednisone—systemic scleroderma	0.000656	0.000656	CcSEcCtD
Gadoversetamide—Feeling abnormal—Lisinopril—systemic scleroderma	0.00065	0.00065	CcSEcCtD
Gadoversetamide—Pruritus—Leflunomide—systemic scleroderma	0.000649	0.000649	CcSEcCtD
Gadoversetamide—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000646	0.000646	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000645	0.000645	CcSEcCtD
Gadoversetamide—Dysuria—Methotrexate—systemic scleroderma	0.000644	0.000644	CcSEcCtD
Gadoversetamide—Dizziness—Azathioprine—systemic scleroderma	0.000643	0.000643	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000629	0.000629	CcSEcCtD
Gadoversetamide—Asthenia—Mycophenolic acid—systemic scleroderma	0.000628	0.000628	CcSEcCtD
Gadoversetamide—Diarrhoea—Leflunomide—systemic scleroderma	0.000628	0.000628	CcSEcCtD
Gadoversetamide—Urticaria—Lisinopril—systemic scleroderma	0.000626	0.000626	CcSEcCtD
Gadoversetamide—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000625	0.000625	CcSEcCtD
Gadoversetamide—Abdominal pain—Lisinopril—systemic scleroderma	0.000623	0.000623	CcSEcCtD
Gadoversetamide—Body temperature increased—Lisinopril—systemic scleroderma	0.000623	0.000623	CcSEcCtD
Gadoversetamide—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.00062	0.00062	CcSEcCtD
Gadoversetamide—Pruritus—Mycophenolic acid—systemic scleroderma	0.000619	0.000619	CcSEcCtD
Gadoversetamide—Vomiting—Azathioprine—systemic scleroderma	0.000618	0.000618	CcSEcCtD
Gadoversetamide—Pneumonia—Methotrexate—systemic scleroderma	0.000617	0.000617	CcSEcCtD
Gadoversetamide—Eye disorder—Prednisone—systemic scleroderma	0.000616	0.000616	CcSEcCtD
Gadoversetamide—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000616	0.000616	CcSEcCtD
Gadoversetamide—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000614	0.000614	CcSEcCtD
Gadoversetamide—Rash—Azathioprine—systemic scleroderma	0.000613	0.000613	CcSEcCtD
Gadoversetamide—Dermatitis—Azathioprine—systemic scleroderma	0.000612	0.000612	CcSEcCtD
Gadoversetamide—Flushing—Prednisone—systemic scleroderma	0.000612	0.000612	CcSEcCtD
Gadoversetamide—Headache—Azathioprine—systemic scleroderma	0.000609	0.000609	CcSEcCtD
Gadoversetamide—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000608	0.000608	CcSEcCtD
Gadoversetamide—Dizziness—Leflunomide—systemic scleroderma	0.000607	0.000607	CcSEcCtD
Gadoversetamide—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000601	0.000601	CcSEcCtD
Gadoversetamide—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000599	0.000599	CcSEcCtD
Gadoversetamide—Angiopathy—Prednisone—systemic scleroderma	0.000598	0.000598	CcSEcCtD
Gadoversetamide—Conjunctivitis—Methotrexate—systemic scleroderma	0.000596	0.000596	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000596	0.000596	CcSEcCtD
Gadoversetamide—Immune system disorder—Prednisone—systemic scleroderma	0.000595	0.000595	CcSEcCtD
Gadoversetamide—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000591	0.000591	CcSEcCtD
Gadoversetamide—Pain—Mycophenolate mofetil—systemic scleroderma	0.000591	0.000591	CcSEcCtD
Gadoversetamide—Arrhythmia—Prednisone—systemic scleroderma	0.000589	0.000589	CcSEcCtD
Gadoversetamide—Haematuria—Methotrexate—systemic scleroderma	0.000585	0.000585	CcSEcCtD
Gadoversetamide—Vomiting—Leflunomide—systemic scleroderma	0.000583	0.000583	CcSEcCtD
Gadoversetamide—Hypersensitivity—Lisinopril—systemic scleroderma	0.000581	0.000581	CcSEcCtD
Gadoversetamide—Dizziness—Mycophenolic acid—systemic scleroderma	0.000579	0.000579	CcSEcCtD
Gadoversetamide—Epistaxis—Methotrexate—systemic scleroderma	0.000579	0.000579	CcSEcCtD
Gadoversetamide—Rash—Leflunomide—systemic scleroderma	0.000579	0.000579	CcSEcCtD
Gadoversetamide—Dermatitis—Leflunomide—systemic scleroderma	0.000578	0.000578	CcSEcCtD
Gadoversetamide—Mental disorder—Prednisone—systemic scleroderma	0.000577	0.000577	CcSEcCtD
Gadoversetamide—Nausea—Azathioprine—systemic scleroderma	0.000577	0.000577	CcSEcCtD
Gadoversetamide—Headache—Leflunomide—systemic scleroderma	0.000575	0.000575	CcSEcCtD
Gadoversetamide—Erythema—Prednisone—systemic scleroderma	0.000574	0.000574	CcSEcCtD
Gadoversetamide—Malnutrition—Prednisone—systemic scleroderma	0.000574	0.000574	CcSEcCtD
Gadoversetamide—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000569	0.000569	CcSEcCtD
Gadoversetamide—Asthenia—Lisinopril—systemic scleroderma	0.000566	0.000566	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000565	0.000565	CcSEcCtD
Gadoversetamide—Pruritus—Lisinopril—systemic scleroderma	0.000558	0.000558	CcSEcCtD
Gadoversetamide—Vomiting—Mycophenolic acid—systemic scleroderma	0.000557	0.000557	CcSEcCtD
Gadoversetamide—Haemoglobin—Methotrexate—systemic scleroderma	0.000554	0.000554	CcSEcCtD
Gadoversetamide—Rash—Mycophenolic acid—systemic scleroderma	0.000552	0.000552	CcSEcCtD
Gadoversetamide—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000551	0.000551	CcSEcCtD
Gadoversetamide—Haemorrhage—Methotrexate—systemic scleroderma	0.000551	0.000551	CcSEcCtD
Gadoversetamide—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000549	0.000549	CcSEcCtD
Gadoversetamide—Headache—Mycophenolic acid—systemic scleroderma	0.000548	0.000548	CcSEcCtD
Gadoversetamide—Pharyngitis—Methotrexate—systemic scleroderma	0.000547	0.000547	CcSEcCtD
Gadoversetamide—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000546	0.000546	CcSEcCtD
Gadoversetamide—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000546	0.000546	CcSEcCtD
Gadoversetamide—Nausea—Leflunomide—systemic scleroderma	0.000545	0.000545	CcSEcCtD
Gadoversetamide—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000544	0.000544	CcSEcCtD
Gadoversetamide—Vision blurred—Prednisone—systemic scleroderma	0.000541	0.000541	CcSEcCtD
Gadoversetamide—Urethral disorder—Methotrexate—systemic scleroderma	0.00054	0.00054	CcSEcCtD
Gadoversetamide—Diarrhoea—Lisinopril—systemic scleroderma	0.000539	0.000539	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Prednisone—systemic scleroderma	0.000532	0.000532	CcSEcCtD
Gadoversetamide—Agitation—Prednisone—systemic scleroderma	0.000527	0.000527	CcSEcCtD
Gadoversetamide—Dizziness—Lisinopril—systemic scleroderma	0.000521	0.000521	CcSEcCtD
Gadoversetamide—Erythema multiforme—Methotrexate—systemic scleroderma	0.000521	0.000521	CcSEcCtD
Gadoversetamide—Nausea—Mycophenolic acid—systemic scleroderma	0.00052	0.00052	CcSEcCtD
Gadoversetamide—Malaise—Prednisone—systemic scleroderma	0.000517	0.000517	CcSEcCtD
Gadoversetamide—Vertigo—Prednisone—systemic scleroderma	0.000516	0.000516	CcSEcCtD
Gadoversetamide—Eye disorder—Methotrexate—systemic scleroderma	0.000515	0.000515	CcSEcCtD
Gadoversetamide—Syncope—Prednisone—systemic scleroderma	0.000515	0.000515	CcSEcCtD
Gadoversetamide—Tinnitus—Methotrexate—systemic scleroderma	0.000514	0.000514	CcSEcCtD
Gadoversetamide—Cardiac disorder—Methotrexate—systemic scleroderma	0.000511	0.000511	CcSEcCtD
Gadoversetamide—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000509	0.000509	CcSEcCtD
Gadoversetamide—Loss of consciousness—Prednisone—systemic scleroderma	0.000504	0.000504	CcSEcCtD
Gadoversetamide—Vomiting—Lisinopril—systemic scleroderma	0.000501	0.000501	CcSEcCtD
Gadoversetamide—Angiopathy—Methotrexate—systemic scleroderma	0.0005	0.0005	CcSEcCtD
Gadoversetamide—Immune system disorder—Methotrexate—systemic scleroderma	0.000498	0.000498	CcSEcCtD
Gadoversetamide—Rash—Lisinopril—systemic scleroderma	0.000497	0.000497	CcSEcCtD
Gadoversetamide—Convulsion—Prednisone—systemic scleroderma	0.000497	0.000497	CcSEcCtD
Gadoversetamide—Dermatitis—Lisinopril—systemic scleroderma	0.000497	0.000497	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000496	0.000496	CcSEcCtD
Gadoversetamide—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000496	0.000496	CcSEcCtD
Gadoversetamide—Hypertension—Prednisone—systemic scleroderma	0.000495	0.000495	CcSEcCtD
Gadoversetamide—Chills—Methotrexate—systemic scleroderma	0.000494	0.000494	CcSEcCtD
Gadoversetamide—Headache—Lisinopril—systemic scleroderma	0.000494	0.000494	CcSEcCtD
Gadoversetamide—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000489	0.000489	CcSEcCtD
Gadoversetamide—Myalgia—Prednisone—systemic scleroderma	0.000488	0.000488	CcSEcCtD
Gadoversetamide—Arthralgia—Prednisone—systemic scleroderma	0.000488	0.000488	CcSEcCtD
Gadoversetamide—Anxiety—Prednisone—systemic scleroderma	0.000487	0.000487	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000485	0.000485	CcSEcCtD
Gadoversetamide—Discomfort—Prednisone—systemic scleroderma	0.000483	0.000483	CcSEcCtD
Gadoversetamide—Mental disorder—Methotrexate—systemic scleroderma	0.000483	0.000483	CcSEcCtD
Gadoversetamide—Erythema—Methotrexate—systemic scleroderma	0.00048	0.00048	CcSEcCtD
Gadoversetamide—Malnutrition—Methotrexate—systemic scleroderma	0.00048	0.00048	CcSEcCtD
Gadoversetamide—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000473	0.000473	CcSEcCtD
Gadoversetamide—Dysgeusia—Methotrexate—systemic scleroderma	0.00047	0.00047	CcSEcCtD
Gadoversetamide—Nausea—Lisinopril—systemic scleroderma	0.000468	0.000468	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Prednisone—systemic scleroderma	0.000468	0.000468	CcSEcCtD
Gadoversetamide—Oedema—Prednisone—systemic scleroderma	0.000468	0.000468	CcSEcCtD
Gadoversetamide—Back pain—Methotrexate—systemic scleroderma	0.000464	0.000464	CcSEcCtD
Gadoversetamide—Shock—Prednisone—systemic scleroderma	0.000461	0.000461	CcSEcCtD
Gadoversetamide—Nervous system disorder—Prednisone—systemic scleroderma	0.000459	0.000459	CcSEcCtD
Gadoversetamide—Tachycardia—Prednisone—systemic scleroderma	0.000457	0.000457	CcSEcCtD
Gadoversetamide—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000457	0.000457	CcSEcCtD
Gadoversetamide—Skin disorder—Prednisone—systemic scleroderma	0.000455	0.000455	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Prednisone—systemic scleroderma	0.000453	0.000453	CcSEcCtD
Gadoversetamide—Vision blurred—Methotrexate—systemic scleroderma	0.000452	0.000452	CcSEcCtD
Gadoversetamide—Anorexia—Prednisone—systemic scleroderma	0.000446	0.000446	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000445	0.000445	CcSEcCtD
Gadoversetamide—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000439	0.000439	CcSEcCtD
Gadoversetamide—Rash—Mycophenolate mofetil—systemic scleroderma	0.000436	0.000436	CcSEcCtD
Gadoversetamide—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000435	0.000435	CcSEcCtD
Gadoversetamide—Headache—Mycophenolate mofetil—systemic scleroderma	0.000433	0.000433	CcSEcCtD
Gadoversetamide—Malaise—Methotrexate—systemic scleroderma	0.000432	0.000432	CcSEcCtD
Gadoversetamide—Vertigo—Methotrexate—systemic scleroderma	0.000431	0.000431	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000427	0.000427	CcSEcCtD
Gadoversetamide—Insomnia—Prednisone—systemic scleroderma	0.000424	0.000424	CcSEcCtD
Gadoversetamide—Paraesthesia—Prednisone—systemic scleroderma	0.00042	0.00042	CcSEcCtD
Gadoversetamide—Cough—Methotrexate—systemic scleroderma	0.000418	0.000418	CcSEcCtD
Gadoversetamide—Convulsion—Methotrexate—systemic scleroderma	0.000415	0.000415	CcSEcCtD
Gadoversetamide—Dyspepsia—Prednisone—systemic scleroderma	0.000412	0.000412	CcSEcCtD
Gadoversetamide—Nausea—Mycophenolate mofetil—systemic scleroderma	0.00041	0.00041	CcSEcCtD
Gadoversetamide—Myalgia—Methotrexate—systemic scleroderma	0.000408	0.000408	CcSEcCtD
Gadoversetamide—Chest pain—Methotrexate—systemic scleroderma	0.000408	0.000408	CcSEcCtD
Gadoversetamide—Arthralgia—Methotrexate—systemic scleroderma	0.000408	0.000408	CcSEcCtD
Gadoversetamide—Decreased appetite—Prednisone—systemic scleroderma	0.000407	0.000407	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000405	0.000405	CcSEcCtD
Gadoversetamide—Fatigue—Prednisone—systemic scleroderma	0.000404	0.000404	CcSEcCtD
Gadoversetamide—Discomfort—Methotrexate—systemic scleroderma	0.000403	0.000403	CcSEcCtD
Gadoversetamide—Constipation—Prednisone—systemic scleroderma	0.0004	0.0004	CcSEcCtD
Gadoversetamide—Confusional state—Methotrexate—systemic scleroderma	0.000395	0.000395	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000391	0.000391	CcSEcCtD
Gadoversetamide—Feeling abnormal—Prednisone—systemic scleroderma	0.000386	0.000386	CcSEcCtD
Gadoversetamide—Nervous system disorder—Methotrexate—systemic scleroderma	0.000384	0.000384	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000383	0.000383	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000383	0.000383	CcSEcCtD
Gadoversetamide—Skin disorder—Methotrexate—systemic scleroderma	0.00038	0.00038	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000378	0.000378	CcSEcCtD
Gadoversetamide—Anorexia—Methotrexate—systemic scleroderma	0.000373	0.000373	CcSEcCtD
Gadoversetamide—Urticaria—Prednisone—systemic scleroderma	0.000372	0.000372	CcSEcCtD
Gadoversetamide—Body temperature increased—Prednisone—systemic scleroderma	0.00037	0.00037	CcSEcCtD
Gadoversetamide—Abdominal pain—Prednisone—systemic scleroderma	0.00037	0.00037	CcSEcCtD
Gadoversetamide—Hypotension—Methotrexate—systemic scleroderma	0.000366	0.000366	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000357	0.000357	CcSEcCtD
Gadoversetamide—Insomnia—Methotrexate—systemic scleroderma	0.000354	0.000354	CcSEcCtD
Gadoversetamide—Paraesthesia—Methotrexate—systemic scleroderma	0.000351	0.000351	CcSEcCtD
Gadoversetamide—Dyspnoea—Methotrexate—systemic scleroderma	0.000349	0.000349	CcSEcCtD
Gadoversetamide—Somnolence—Methotrexate—systemic scleroderma	0.000348	0.000348	CcSEcCtD
Gadoversetamide—Hypersensitivity—Prednisone—systemic scleroderma	0.000345	0.000345	CcSEcCtD
Gadoversetamide—Dyspepsia—Methotrexate—systemic scleroderma	0.000344	0.000344	CcSEcCtD
Gadoversetamide—Decreased appetite—Methotrexate—systemic scleroderma	0.00034	0.00034	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000338	0.000338	CcSEcCtD
Gadoversetamide—Fatigue—Methotrexate—systemic scleroderma	0.000337	0.000337	CcSEcCtD
Gadoversetamide—Asthenia—Prednisone—systemic scleroderma	0.000336	0.000336	CcSEcCtD
Gadoversetamide—Pain—Methotrexate—systemic scleroderma	0.000335	0.000335	CcSEcCtD
Gadoversetamide—Pruritus—Prednisone—systemic scleroderma	0.000331	0.000331	CcSEcCtD
Gadoversetamide—Feeling abnormal—Methotrexate—systemic scleroderma	0.000323	0.000323	CcSEcCtD
Gadoversetamide—Diarrhoea—Prednisone—systemic scleroderma	0.00032	0.00032	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.00032	0.00032	CcSEcCtD
Gadoversetamide—Urticaria—Methotrexate—systemic scleroderma	0.000311	0.000311	CcSEcCtD
Gadoversetamide—Dizziness—Prednisone—systemic scleroderma	0.00031	0.00031	CcSEcCtD
Gadoversetamide—Abdominal pain—Methotrexate—systemic scleroderma	0.000309	0.000309	CcSEcCtD
Gadoversetamide—Body temperature increased—Methotrexate—systemic scleroderma	0.000309	0.000309	CcSEcCtD
Gadoversetamide—Vomiting—Prednisone—systemic scleroderma	0.000298	0.000298	CcSEcCtD
Gadoversetamide—Rash—Prednisone—systemic scleroderma	0.000295	0.000295	CcSEcCtD
Gadoversetamide—Dermatitis—Prednisone—systemic scleroderma	0.000295	0.000295	CcSEcCtD
Gadoversetamide—Headache—Prednisone—systemic scleroderma	0.000293	0.000293	CcSEcCtD
Gadoversetamide—Hypersensitivity—Methotrexate—systemic scleroderma	0.000288	0.000288	CcSEcCtD
Gadoversetamide—Asthenia—Methotrexate—systemic scleroderma	0.000281	0.000281	CcSEcCtD
Gadoversetamide—Nausea—Prednisone—systemic scleroderma	0.000278	0.000278	CcSEcCtD
Gadoversetamide—Pruritus—Methotrexate—systemic scleroderma	0.000277	0.000277	CcSEcCtD
Gadoversetamide—Diarrhoea—Methotrexate—systemic scleroderma	0.000268	0.000268	CcSEcCtD
Gadoversetamide—Dizziness—Methotrexate—systemic scleroderma	0.000259	0.000259	CcSEcCtD
Gadoversetamide—Vomiting—Methotrexate—systemic scleroderma	0.000249	0.000249	CcSEcCtD
Gadoversetamide—Rash—Methotrexate—systemic scleroderma	0.000247	0.000247	CcSEcCtD
Gadoversetamide—Dermatitis—Methotrexate—systemic scleroderma	0.000247	0.000247	CcSEcCtD
Gadoversetamide—Headache—Methotrexate—systemic scleroderma	0.000245	0.000245	CcSEcCtD
Gadoversetamide—Nausea—Methotrexate—systemic scleroderma	0.000232	0.000232	CcSEcCtD
